For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.
Ipamorelin research dates to a 1998 paper that described it as “the first selective growth hormone secretagogue” [1]. Ipamorelin is a synthetic pentapeptide identified in a chemistry program built on growth hormone-releasing peptides (GHRPs). In rat pituitary cells it released growth hormone (GH) with potency and efficacy similar to GHRP-6, acting through a GHRP-like receptor [1]. Its selectivity is what distinguished it: in swine, ipamorelin did not raise ACTH or cortisol above the levels seen with GHRH, unlike GHRP-6 and GHRP-2 [1].
What is ipamorelin? Structure
| Property | Value |
|---|---|
| Type | Synthetic pentapeptide GH secretagogue [1] |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ [1] |
| Formula / MW | C₃₈H₄₉N₉O₅ / ~711.9 g/mol (PubChem CID 9831659) |
| Receptor | GHRP-like receptor [1] |
| Form supplied by MFP | Supplied as a lyophilized powder for laboratory research |
Ipamorelin studies: key findings
From the 1998 discovery paper [1]:
- In vitro: in primary rat pituitary cells, ipamorelin released GH with an EC₅₀ of 1.3 nmol/L and Emax of 85%, compared with 2.2 nmol/L and 100% for GHRP-6.
- Receptor pharmacology: GHRP and GHRH antagonist profiling showed that ipamorelin, like GHRP-6, acts through a GHRP-like receptor.
- Selectivity in swine: none of the secretagogues tested changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol; ipamorelin did not raise them significantly above GHRH levels, even at concentrations far above those needed for GH release.
A 1999 rat study reported increases in longitudinal bone growth rate with ipamorelin, without changes in total IGF-I, IGF-binding proteins or serum bone markers [2].
Ipamorelin vs other GH secretagogues
| Ipamorelin | GHRP-6 / GHRP-2 | CJC-1295 | |
|---|---|---|---|
| Class | GHRP-receptor agonist [1] | GHRP-receptor agonists [1] | GHRH analog |
| ACTH/cortisol in swine | Not significantly raised [1] | Raised [1] | Not compared in [1] |
| Related article | — | — | CJC-1295 With vs Without DAC |
Regulatory status
FDA lists ipamorelin acetate in Category 2 of bulk drug substances nominated for compounding that may present significant safety risks [3]. Ipamorelin is not FDA-approved for any use.
Frequently asked questions
A synthetic pentapeptide growth hormone secretagogue that acts through a GHRP-like receptor [1].
In swine it released GH without significantly raising ACTH or cortisol, unlike GHRP-6 and GHRP-2 [1].
Ipamorelin is a GHRP-receptor agonist; CJC-1295 is an analog of growth hormone-releasing hormone (GHRH), which acts on a different receptor.
No. FDA lists ipamorelin acetate in Category 2 [3].
Research materials and certificates
- Ipamorelin · Ipamorelin + CJC-1295 Combo · COA Library
- Related: CJC-1295 With vs Without DAC · Peptide Acetate vs TFA Salt
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552. PMID: 9849822
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. doi:10.1054/ghir.1999.9998. PMID: 10373343
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov
Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.
